The Role and Mechanism of Incretins in Gynaecologic Diseases
Endocrinology, Diabetes & Metabolism · 2026-09 · 9 (5)
DOI: 10.1002/edm2.70340 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 25.09.2026. Verfasst von Jiayu Yan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity …. Hauptthemen laut MEDLINE: Incretins, Genital Diseases, Female. Die Arbeit nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Pujiang Program, Shanghai Medical Star of Tomorrow Youth Medical Talent Development Funding Program.
Abstract (Originalsprache)
Background
Obesity is a major global public health concern closely linked to the development and progression of various gynaecological disorders, particularly polycystic ovary syndrome (PCOS) and endometrial cancer. Incretins, a group of gut‐derived hormones primarily including glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP), are widely recognised for their roles in glycemic control and insulin secretion. Accumulating evidence reveals that GLP‐1 and GIP also participate in modulating inflammation, autophagy, immune response and gut‐brain communication through multiple signalling pathways, thereby playing important roles in female reproductive disorders. This review provides a comprehensive overview of the mechanisms and therapeutic potential of incretins in gynaecological conditions.
Methods
We performed a comprehensive literature search across PubMed, Web of Science and Embase, covering studies published from January 1995 to July 2026. Search terms combined incretin‐related keywords (GLP‐1, GIP, GLP‐1 receptor agonists) with gynaecological disease terms (polycystic ovary syndrome, endometriosis, endometrial cancer, ovarian cancer, intrauterine adhesion). We primarily included original research studies and authoritative reviews, and excluded meeting abstracts, case reports and non‐English literature.
Results
GLP‐1 receptor agonists (GLP‐1 RAs) exert multi‐faceted benefits in PCOS, endometriosis, intrauterine adhesions and gynaecologic cancers through cAMP/PKA, PI3K and AMPK signalling pathways. Special emphasis is placed on the multi‐faceted benefits of GLP‐1 RAs, while evidence supporting GIP‐based therapies in gynaecology remains relatively limited and largely preclinical. The current status of clinical application, safety considerations and future directions are further discussed.
Conclusion
Incretin‐based therapies offer novel approaches for metabolic and oncological gynaecological diseases, with significant translational value. Large‐scale clinical studies and deeper mechanistic exploration are warranted to realise their full therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai,…
ORCID-Profile: Jiayu Yan, Yiqin Zhang, Yanli Zhang, Bilan Li
Förderung
- National Natural Science Foundation of China
- Shanghai Pujiang Program
- Shanghai Medical Star of Tomorrow Youth Medical Talent Development Funding Program
- Shanghai Shenkang Hospital Development Center
- Shanghai Oriental Talents
- Clinical Research Program of Shanghai First Maternity and Infant Hospital
- Shanghai Municipal Hospital Development Center
Zitieren
APA
Yan, J., Cao, M., Ding, Y., Zhang, Y., Sun, Y., Jiang, G., Zhang, Y., Kang, L., Zhou, X., Luo, J., & Li, B. (2026). The Role and Mechanism of Incretins in Gynaecologic Diseases. Endocrinology, Diabetes & Metabolism, 9(5). https://doi.org/10.1002/edm2.70340
Vancouver
Yan J, Cao M, Ding Y, Zhang Y, Sun Y, Jiang G, et al. The Role and Mechanism of Incretins in Gynaecologic Diseases. Endocrinology, Diabetes & Metabolism. 2026;9(5). doi:10.1002/edm2.70340
BibTeX
@article{Yan2026,
author = {Yan, Jiayu and Cao, Minyue and Ding, Yan and Zhang, Yiqin and Sun, Yihan and Jiang, Genyi and Zhang, Yanli and Kang, Luyao and Zhou, Xue and Luo, Jing and Li, Bilan},
title = {The Role and Mechanism of Incretins in Gynaecologic Diseases},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
volume = {9},
number = {5},
doi = {10.1002/edm2.70340}
}
EUVIMED